RETATRUTIDE 40MG

Retatrutide is one of the most promising new weight-loss and metabolic health drugs currently in clinical development. Unlike existing GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) or dual agonists like tirzepatide (Mounjaro, Zepbound), Retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors simultaneously. This unique mechanism has shown unprecedented results in early clinical trials, with participants losing over 24% of their body weight in less than a year at the highest studied doses.

15 CLICKS = 2MG 

Retatrutide (also known as LY-3437943) is an experimental medication developed by Eli Lilly that is being studied as a next-generation treatment for obesity, overweight, and related metabolic conditions such as type 2 diabetes. It represents a new class of therapies called “triple agonists,” meaning it simultaneously activates three key hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This combined activity helps regulate appetite, improve insulin sensitivity, slow gastric emptying to promote fullness, and enhance fat burning.

Key Points:

• Retatrutide is given as a once-weekly subcutaneous injection.
• Stepwise escalation is critical to reduce gastrointestinal intolerance.
• Most participants in trials reached 8–12 mg weekly, which delivered the strongest results.
• Dosing protocols may be refined in Phase 3 and post-approval, but gradual titration will remain the standard.

Dosing Protocol : 
Suggested weekly titration approach from clinical trials.

• Start : 2mg weekly for 4 weeks to assess tolerance.
• Escalate : Increase by 2-4 mg every 4 weeks as tolerated.
• Target : 6-8 mg weekly (standard), 12mg weekly (advanced/aggressive).
• Frequency : Once per week (subcutaneous), same day each week.
• Cycle Length : Minimum 24 weeks; trials extended to 48 weeks.
• Timing : Any consistent day/time; rotate injection sites with each dose.

Weeks 1-4 : 2mg = 15 clicks
Weeks 5-8 : 4mg = 30 clicks
Weeks 9-12 : 8mg = 60 clicks
Weeks 13+ : 12mg = 90 clicks

Common Side Effects :

Across Phase 2 trials, participants experienced dose-dependent GI symptoms that are characteristic of GLP-1 receptor agonists:

• Nausea — most frequent, especially during dose escalation
• Vomiting — typically mild to moderate, subsiding with continued use
• Diarrhea and constipation — fluctuating depending on individual tolerance
• Abdominal discomfort — transient and often improved over time